Global drug developers like Sanofi-Aventis, GlaxoSmithKline and Novartis are investing heavily in their vaccine operations as governments around the world beef up stockpiles in hopes of warding off an outbreak of an avian flu pandemic. That's a big switch for the low-profile vaccine business, which commands a mere 2 percent of the world's drug revenues. But analysts say the push to prepare for a pandemic will cause that figure to triple over the next six years.
- read this report from Today Online for more
PLUS: Australia is increasing the supplies of Tamiflu it is sending to Indonesia to help fight the spread of avian flu. Story